Type 1 diabetes (T1D) is an autoimmune disorder that affects the lives of millions of people, in which the body attacks and destroys its own insulin producing cells, thus dysregulating blood sugar levels essential to normal bodily function. Individuals with a high risk for developing T1D can now be identified with a combination of genotyping and serological testing. People in this high risk population who are identified in the early stages of the disease present a unique treatment and reversal of disease opportunity. We and our colleagues have established an effective vaccine that thwarts the “auto-destruction” of insulin producing cells necessary for normalglycemia. However, this first version of our vaccine requires the processing large numbers of patient cells. This project’s goal is to develop a nanoparticle-based vaccine that works as efficiently as the cell-based version........... After manufacturing these nanoparticles, we will test their efficacy in NOD model for T1D and in a ..... These experiments will give us an excellent idea of the feasibility and safety of this treatment to be eventually translated in a future clinical setting.
|Effective start/end date||2/1/18 → 1/31/21|
- JDRF International (3-PDF-2018-580-A-N)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.